Mo1834 Dose Escalated Vedolizumab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program

Jack McNamara; Basheer Alshiwanna; William E. Wilson; Joseph L. Pipicella; Simon Ghaly; Richard Gearry; Jakob Begun; Watson Ng; Kate D. Lynch; Ian C. Lawrance; Michael Schultz; Gareth J. Walker; Graham L. Radford-Smith; Jane M. Andrews; Susan J. Connor

doi:10.1016/S0016-5085(24)03073-7

Back

Mo1834 Dose Escalated Vedolizumab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program

Conference paper

Peer reviewed

Mo1834 Dose Escalated Vedolizumab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program

Jack McNamara, Basheer Alshiwanna, William E. Wilson, Joseph L. Pipicella, Simon Ghaly, Richard Gearry, Jakob Begun, Watson Ng, Kate D. Lynch, Ian C. Lawrance, …

Gastroenterology (New York, N.Y. 1943), Vol.166(5), p.S-1135

18/05/2024

DOI: https://doi.org/10.1016/S0016-5085(24)03073-7

Handle:

https://hdl.handle.net/10523/40919

Metrics

12 Record Views

Details

Record Identifier: 9926556037701891
Title: Mo1834 Dose Escalated Vedolizumab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program
Creators: Jack McNamara
Basheer Alshiwanna
William E. Wilson
Joseph L. Pipicella
Simon Ghaly
Richard Gearry
Jakob Begun
Watson Ng
Kate D. Lynch
Ian C. Lawrance
Michael Schultz
Gareth J. Walker
Graham L. Radford-Smith
Jane M. Andrews
Susan J. Connor
Publication Details: Gastroenterology (New York, N.Y. 1943), Vol.166(5), p.S-1135
Academic Unit: Medicine (DSM); Medicine (UOC)
Date published ; e-published: 18/05/2024
Language: English
Resource Type ; Subtype: Conference paper; Conference Abstract

Mo1834 Dose Escalated Vedolizumab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program

Related links

Metrics

Details